South African pharmaceutical group Adcock Ingram says its businesses in Zimbabwe and Kenya have continued to underperform, cumulatively incurring a trading loss of $69 000 in the six months to December, 2016.
The Johannesburg listed company has interests in flagging Bulawayo-based pharmaceutical manufacturer and distributor Datlabs, whose production capacity has been going down due to operational challenges.
“The units in Zimbabwe and Kenya have for some time underperformed in challenging markets. These entities fortunately constitute a very small percentage of Group assets and collectively incurred a trading loss of R0.9 million during the period under review,” the company said in its unaudited group interim results for the six months ended 31 December 2016.
Datlabs produces leading brands such as Cafemol, Panado, Solphyllex and Lanolene Milk under licence but has been facing serious competition from imports mainly from the Asian bloc.
The company has been seeking close to $10 million to recapatilise its operations.-The Source
(51 VIEWS)
The gazetting into law of the payment of quarterly taxes on a 50-50 basis in…
Zimbabwe has today unveiled a ZiG276.4 billion budget for 2025 during which it expects the…
Zimbabwe President Emmerson Mnangagwa has repeatedly stated that he is not going to contest a…
The Zimbabwe Gold fell against the United States dollar for five consecutive days from Monday…
An Indian think tank has described Starlink, a satellite internet service provider which recently entered…
Zimbabwe’s new currency, the Zimbabwe Gold (ZiG), firmed against the United States dollars for 10…